-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, the revitalization of traditional Chinese medicine has become a national strate.
With the promotion of a series of policies to encourage and support the development of traditional Chinese medicine, such as the "Guiding Opinions on Inheriting and Innovative Development", the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for clinical trials of new Chinese medicines and new drug marketing authorization applications has also increased year by ye.
According to the data, in terms of new drug clinical trials, there will be 78 traditional Chinese medicines in 2021, an increase of 14% over 202Judging from the indications of these clinical trials, they are mainly concentrated in the fields of neuropsychiatry, digestion, and respirati.
In addition, in terms of new drug listing, in 2021, China will approve 12 new traditional Chinese medicine drugs, which has exceeded the total of the past four yea.
In the first half of this year, a number of new TCM Class 1 drugs have been approved one after anoth.
For example, Jianmin Group announced on January 4 this year that the company's 1 innovative traditional Chinese medicine Qirui Weishu Capsule was approved for listi.
On January 10, Huadong Medicine's 2 class innovative drug Icariin Soft Capsule was approved for marketing with conditions through the priority review and approval proce.
At the beginning of March, Yunnan Baiyao's new class 1 traditional Chinese medicine "Quansanqi Tablets" was approved by the State Food and Drug Administration to carry out clinical trials for chest tightness and heartache caused by blood stas.
Since the second half of the year, a number of new Class 1 Chinese medicine drugs have been submitted for clinical applicatio.
For example, Qingfei Dayuan Granules, a class 1 new drug of traditional Chinese medicine, has obtained an implied license for clinical trials, and is the first class of new Chinese patent medicines for colds that has been declared and approved for clinical trials since the beginning of this ye.
In addition, the clinical application of Qingfei Dayuan Granules submitted by Jinpai Chizhengtang Pharmaceutical as a new type of Chinese medicine 1 was accepted by CDE in May 2022, and has also been approved for clinical use in the treatment of influenza Lung syndrome, symptoms include fever, aversion to cold, nasal congestion and runny nose, cough, sore throat, muscle pain, headache, fatigue, chest tightness,e.
On the whole, with the continuous promotion of favorable policies for traditional Chinese medicine and the continuous approach of comprehensive centralized procurement of Chinese patent medicines, more and more domestic pharmaceutical companies realize the importance of innovation and upgrading, and the research and development of new traditional Chinese medicines is becoming more and more popul.
The research and development results are also increasingly fruitf.
However, it should be noted that although the research and development of new Chinese medicines has entered a period of rapid development and is gradually entering a period of harvest, there are still many difficulties and pain points in research and development, especially in terms of technological competitiveness and research innovati.
There are deficienci.
For example, at present, most traditional Chinese medicine companies tend to be homogenized in the field of drug research and development, and the innovation attribute is not obvio.
It is understood that among the 60 new drug applications of traditional Chinese medicines accepted by CDE in 2021, digestive system, respiratory system, and cardiovascular and cerebrovascular diseases are still the top three drug fields for new drug applications of traditional Chinese medicin.
It can be seen that the core competitiveness of new Chinese medicine research and development needs to be further improved, including the patented technical value and commercial value of prescriptio.
In general, with the implementation of relevant national policies to promote the development of traditional Chinese medicine and the continuous improvement of technical guiding principles, the research and development of new traditional Chinese medicines will enter a bumper peri.
However, in the long run, if the traditional Chinese medicine industry wants to embark on the road of high-quality development, there is still a long way to go and continuous efforts are requir.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
With the promotion of a series of policies to encourage and support the development of traditional Chinese medicine, such as the "Guiding Opinions on Inheriting and Innovative Development", the ability of traditional Chinese medicine to inherit and innovate has been significantly enhanced, and the number of applications for clinical trials of new Chinese medicines and new drug marketing authorization applications has also increased year by ye.
According to the data, in terms of new drug clinical trials, there will be 78 traditional Chinese medicines in 2021, an increase of 14% over 202Judging from the indications of these clinical trials, they are mainly concentrated in the fields of neuropsychiatry, digestion, and respirati.
In addition, in terms of new drug listing, in 2021, China will approve 12 new traditional Chinese medicine drugs, which has exceeded the total of the past four yea.
In the first half of this year, a number of new TCM Class 1 drugs have been approved one after anoth.
For example, Jianmin Group announced on January 4 this year that the company's 1 innovative traditional Chinese medicine Qirui Weishu Capsule was approved for listi.
On January 10, Huadong Medicine's 2 class innovative drug Icariin Soft Capsule was approved for marketing with conditions through the priority review and approval proce.
At the beginning of March, Yunnan Baiyao's new class 1 traditional Chinese medicine "Quansanqi Tablets" was approved by the State Food and Drug Administration to carry out clinical trials for chest tightness and heartache caused by blood stas.
Since the second half of the year, a number of new Class 1 Chinese medicine drugs have been submitted for clinical applicatio.
For example, Qingfei Dayuan Granules, a class 1 new drug of traditional Chinese medicine, has obtained an implied license for clinical trials, and is the first class of new Chinese patent medicines for colds that has been declared and approved for clinical trials since the beginning of this ye.
In addition, the clinical application of Qingfei Dayuan Granules submitted by Jinpai Chizhengtang Pharmaceutical as a new type of Chinese medicine 1 was accepted by CDE in May 2022, and has also been approved for clinical use in the treatment of influenza Lung syndrome, symptoms include fever, aversion to cold, nasal congestion and runny nose, cough, sore throat, muscle pain, headache, fatigue, chest tightness,e.
On the whole, with the continuous promotion of favorable policies for traditional Chinese medicine and the continuous approach of comprehensive centralized procurement of Chinese patent medicines, more and more domestic pharmaceutical companies realize the importance of innovation and upgrading, and the research and development of new traditional Chinese medicines is becoming more and more popul.
The research and development results are also increasingly fruitf.
However, it should be noted that although the research and development of new Chinese medicines has entered a period of rapid development and is gradually entering a period of harvest, there are still many difficulties and pain points in research and development, especially in terms of technological competitiveness and research innovati.
There are deficienci.
For example, at present, most traditional Chinese medicine companies tend to be homogenized in the field of drug research and development, and the innovation attribute is not obvio.
It is understood that among the 60 new drug applications of traditional Chinese medicines accepted by CDE in 2021, digestive system, respiratory system, and cardiovascular and cerebrovascular diseases are still the top three drug fields for new drug applications of traditional Chinese medicin.
It can be seen that the core competitiveness of new Chinese medicine research and development needs to be further improved, including the patented technical value and commercial value of prescriptio.
In general, with the implementation of relevant national policies to promote the development of traditional Chinese medicine and the continuous improvement of technical guiding principles, the research and development of new traditional Chinese medicines will enter a bumper peri.
However, in the long run, if the traditional Chinese medicine industry wants to embark on the road of high-quality development, there is still a long way to go and continuous efforts are requir.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
